Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

34.21
-0.5400-1.55%
Post-market: 34.210.00000.00%19:30 EDT
Volume:6.40M
Turnover:218.05M
Market Cap:24.71B
PE:-72.79
High:34.56
Open:34.28
Low:33.32
Close:34.75
52wk High:42.50
52wk Low:15.90
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.26
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.84
PE(LYR):-63.35

Loading ...

Immunovant Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 20

Movement Alert|Roivant Sciences Rises 8.12% in Pre-Market Trading, Reports Fiscal Q4 Results and Business Updates

Market Focus
·
May 20

S&P 500 Futures Rise In Premarket Trading; Immunovant, ImmunityBio Lead

Dow Jones
·
May 20

Roivant Sciences Swings to Fiscal Q4 Net Income, Revenue Decreases

MT Newswires Live
·
May 20

Stock Track | Roivant Sciences Soars 9.89% in Pre-Market on Unexpected Q4 Profit from Moderna Lawsuit Settlement

Stock Track
·
May 20

Immunovant Inc Q4 net loss misses on higher R&D costs

Reuters
·
May 20

Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain

Reuters
·
May 20

Earnings Flash (ROIV) Roivant Posts Fiscal Q4 EPS From Continuing Operations $0.28

MT Newswires Live
·
May 20

Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million

Reuters
·
May 20

Roivant Sciences Q4 Sales $2.520M Miss $3.820M Estimate

Benzinga Earnings
·
May 20

BRIEF-Roivant Sciences Q4 Revenue USD 2.52 Million

Reuters
·
May 20

Immunovant Q4 net loss widens to $147.86 million

Reuters
·
May 20

Roivant Sciences Q4 Operating Expenses USD 357.515 Million

THOMSON REUTERS
·
May 20

Roivant Sciences Q4 EPS USD 0.28

THOMSON REUTERS
·
May 20

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

THOMSON REUTERS
·
May 20

A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus

Simply Wall St.
·
May 19

Roivant Sciences price target raised to $29.50 from $29 at BofA

TIPRANKS
·
May 14

Earning Preview: Roivant Sciences Ltd. revenue is expected to decrease by 92.94%, institutional views are bullish

Earnings Agent
·
May 13

Immunovant to report fourth-quarter, fiscal-year results, give business update on conference call

Reuters
·
May 12

Roivant schedules quarterly, fiscal-year results call and webcast

Reuters
·
May 12